Carregant...
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and about 40–50% of women who respond to initial treatment relapse within 2 years. In the recurrent setting, second-line chemotherapeutic agents have a 15–20% response rate with no cures. Fortunately, clinical...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3199129/ https://ncbi.nlm.nih.gov/pubmed/20226736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(09)70362-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|